| Standard (N = 16) | Experimental (N = 14) | Total (N = 30) | p value |
---|---|---|---|---|
Median age, years (range) | 57.2 (39.6–74.9) | 53.1 (27.8–69.7) | 54.7 (27.8–74.9) | 0.42 |
Race/ethnicity | Â | Â | Â | 0.71 |
 Caucasian | 11 (68.8%) | 7 (50.0%) | 18 (60.0%) |  |
 Hispanic | 4 (25.0%) | 5 (35.7%) | 9 (30.0%) |  |
 African American | 0 (0.0%) | 1 (7.1%) | 1 (3.3%) |  |
 Asian | 1 (6.3%) | 1 (7.1%) | 2 (6.7%) |  |
Tumor type | Â | Â | Â | 0.21 |
 Invasive ductal carcinoma | 16 (100%) | 12 (85.7%) | 28 (93.3%) |  |
 Invasive lobular carcinoma | 0 (0.0%) | 1 (7.1%) | 1 (3.3%) |  |
 Invasive mammary carcinoma | 0 (0.0%) | 1 (7.1%) | 1 (3.3%) |  |
Stage | Â | Â | Â | 0.72 |
 Stage II | 7 (43.8%) | 8 (57.1%) | 15 (50.0%) |  |
 Stage III | 9 (56.3%) | 6 (42.9%) | 15 (50.0%) |  |
Hormone status | Â | Â | Â | Â |
 ER negative | 8 (50%) | 6 (43%) | 14 (46.6%) |  |
 ER positive | 8 (50%) | 8 (57.1%) | 16 (53.3%) |  |
Grade | Â | Â | Â | 0.27 |
 Grade 2 | 5 (31.3%) | 8 (57.1%) | 13 (43.3%) |  |
 Grade 3 | 11 (68.8%) | 6 (42.9%) | 17 (56.7%) |  |
 Ki-67 | 50.5 (2--80) | 55.9 (15–80) | 53.2 (15–80) | 0.54 |